Senti Biosciences to spin off SENTI-202 pipeline to Celadon affiliate, retain gene-circuit platform

Senti Biosciences Holdings, Inc. disclosed in an 8-K that on July 14, 2026, it entered into an agreement with a private affiliate of its largest stockholder, Celadon Partners, under which that affiliate would acquire substantially all of the Company's existing business and pipeline through a merger transaction.¹ Under the deal structure, the company is expected to remain public with a significantly streamlined operating structure, keeping certain intellectual property, collaborations and early-stage programs tied to its Regulator Dial platform, while the rest of the business merges into the private company.¹

Mechanically, the transaction runs through an Agreement and Plan of Merger among the company, Celadon Partners SPV 35 Limited as parent, a merger sub, and Senti subsidiaries Senti Holdings and Senti Biosciences, with Merger Sub to be merged with and into Midco, with Midco continuing as the surviving corporation and a wholly owned subsidiary of Parent.¹

Stockholders will not receive cash directly but contingent value rights. Each CVR represents the right to a pro rata share of $10.0 million upon FDA acceptance of a BLA for SENTI-202, $20.0 million upon FDA approval of that BLA, and $30.0 million if cumulative worldwide net sales of SENTI-202 exceed $200.0 million, all before a seven-year milestone expiration date.¹ The filing cautions that there is no assurance the milestones will be achieved or that any payments will be made.¹

Financially, the company said its cash and cash equivalents were an estimated $6.5 million as of June 30, 2026,¹ which it said, combined with additional funding, are expected to fund operations through the expected closing of the merger and into approximately the fourth quarter of 2026.¹ The company expects the transaction to close in the third quarter of 2026,¹ subject to stockholder approval, with an annual meeting scheduled for August 18, 2026.